( NASDAQ-NMS:VNDA )

News from Vanda Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 15, 2017, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended...


Jan 19, 2017, 16:30 ET Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017

Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth...


Jan 09, 2017, 07:00 ET Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies...


Dec 07, 2016, 18:45 ET Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Apotex

Vanda Grants Apotex a license to sell generic Fanapt® beginning November 2027 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it...


Nov 14, 2016, 17:00 ET Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in...


Nov 02, 2016, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30,...


Oct 24, 2016, 16:01 ET Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreement (the License Agreement) with Taro...


Oct 12, 2016, 16:30 ET Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 2, 2016

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2016 on Wednesday, November 2,...


Aug 30, 2016, 15:00 ET USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and...


Aug 25, 2016, 14:51 ET Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the...


Aug 01, 2016, 07:00 ET HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ® (tasimelteon) is now available for the treatment of...


Jul 27, 2016, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30,...


Jul 12, 2016, 16:30 ET Vanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July...


Jun 20, 2016, 17:00 ET Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will...


Jun 15, 2016, 07:00 ET FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted three years of...


Jun 03, 2016, 07:00 ET Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare...


May 04, 2016, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31,...


Feb 10, 2016, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended...


Feb 01, 2016, 16:30 ET Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel...


Jan 22, 2016, 09:20 ET Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10,...


Jan 11, 2016, 06:55 ET Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel...


Dec 22, 2015, 16:30 ET European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorization Application (MAA) for oral Fanaptum®...


Dec 18, 2015, 07:00 ET Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that Kenneth Bate, an independent biotechnology industry consultant, has joined...


Dec 17, 2015, 16:01 ET Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has appointed Gian Piero Reverberi to the role of Senior Vice President,...


Nov 12, 2015, 18:00 ET Vanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...